Pelago Bioscience
Pelago Bioscience at a glance
Pelago Bioscience is a drug discovery focused CRO with a service offering centred around its patented Cellular Thermal Shift Assay (CETSA®) technology for target engagement assessment in whole-cell physiological conditions. The business model combines CETSA services and license agreements with blue-chip pharma customers. Pelago Bioscience serves a global customer base from its state-of-the-art facilities in Solna, Sweden.
Pelago Bioscience facts
Sector
Specialist Pharma Services
Impilo entry date
August 2023
HQ
Solna, Sweden
Management team
Michael Dabrowski (CEO)
Kia Pedersen (COO)
Impilo team
Victor Steien
Edvard Hubendick
Paula Johansson
No of FTEs
52
Investment thesis
- Sizeable market growing at 10%+ p.a. driven by increasing drug development pipelines, enhanced complexity in novel compound-design and shift towards outsourcing
- Unique value proposition (patented CETSA technology) and an opportunity to capture market share
- Scope to drive M&A in the drug discovery space to accelerate expansion and complement service offering
UN SDG Goals
Other portfolio companies
Oticon Medical
Oticon Medical is a global hearing healthcare company specializing in bone-anchored hearing solutions (BAHS), a niche segment addressing conductive hearing loss.
Read More
Qufora
Qufora is a fast-growing Danish medical technology product company with focus on transanal irrigation (“TAI”) products and collecting devices
Read More
Avia Pharma
Avia is a leading North European OTC/Rx platform
Read More